Atacicept in multiple sclerosis (ATAMS): a randomised, placebo-controlled, double-blind, phase 2 trial-Reference-Cited by-同舟云学术

Atacicept in multiple sclerosis (ATAMS): a randomised, placebo-controlled, double-blind, phase 2 trial

Published:2014-04 Issue:4 Volume:13 Page:353-363
ISSN:1474-4422
Container-title:The Lancet Neurology
language:en
Short-container-title:The Lancet Neurology

Author:

Kappos Ludwig,Hartung Hans-Peter,Freedman Mark S,Boyko Alexey,Radü Ernst Wilhelm,Mikol Daniel D,Lamarine Marc,Hyvert Yann,Freudensprung Ulrich,Plitz Thomas,van Beek Johan

Publisher

Elsevier BV

Subject

Neurology (clinical)

Reference33 articles.

1. Rituximab in relapsing-remitting multiple sclerosis: a 72-week, open-label, phase I trial;Bar-Or;Ann Neurol,2008

2. Rituximab in patients with primary progressive multiple sclerosis: results of a randomized double-blind placebo-controlled multicenter trial;Hawker;Ann Neurol,2009

3. Ocrelizumab in relapsing-remitting multiple sclerosis: a phase 2, randomised, placebo-controlled, multicentre trial;Kappos;Lancet,2011

4. Rituximab add-on therapy for breakthrough relapsing multiple sclerosis: a 52-week phase II trial;Naismith;Neurology,2010

5. B-cell depletion with rituximab in relapsing-remitting multiple sclerosis;Hauser;N Engl J Med,2008

Cited by 280 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Pathogenic Immunoglobulin A-Producing Cells in Immunoglobulin A Nephropathy;Journal of Clinical Medicine;2024-09-05

2. Enhanced and cross-reactive in vitro memory B cell response against Epstein-Barr virus nuclear antigen 1 in multiple sclerosis;Frontiers in Immunology;2024-08-27

3. Experience with the use of cladribine tablets in real-life clinical practice: independent analysis of data from 12 Russian clinical centres;Neurology, Neuropsychiatry, Psychosomatics;2024-08-07

4. New views on the complex interplay between degeneration and autoimmunity in multiple sclerosis;Frontiers in Cellular Neuroscience;2024-08-05

5. Anti-B-Cell-Activating Factor (BAFF) Therapy: A Novel Addition to Autoimmune Disease Management and Potential for Immunomodulatory Therapy in Warm Autoimmune Hemolytic Anemia;Biomedicines;2024-07-18